Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Diana Libster"'
Autor:
Shlomzion Aumann, Uria Tsubary, Boaz Nachmias, Dina Ben Yehuda, David Lavie, Neta Goldschmidt, Vladimir Vainstein, Diana Libster, Revital Saban, Adir Shaulov, Sarah Israel, Batia Avni, Sigal Grisariu, Tali Bdolah‐Amram, Moshe Gatt, Eran Zimran
Publikováno v:
European Journal of Haematology.
Autor:
Ofrat Beyar Katz, Chava Perry, Sigal Grisariu‐Greenzaid, Dana Yehudai‐Ofir, Efrat Luttwak, Batia Avni, Tsila Zuckerman, Inbal Sdayoor, Polina Stepensky, Shimrit Ringelstein‐Harlev, Yael Bar‐On, Diana Libster, Liat Sharvit, Odelia Amit, Uri Greenbaum, Ronit Gold, Yair Herishanu, Noam Benyamini, Irit Avivi, Ron Ram
Publikováno v:
European Journal of Haematology.
Autor:
Ofrat Beyar-Katz, Chava Perry, Yael Bar-On, Sigal Grisariu, Dana Yehudai-Ofir, Efrat Luttwak, Batia Avni, Tsila Zuckerman, Inbal Sdayoor, Polina Stepensky, Shimrit Ringelstein-Harlev, Diana Libster, Liat Sharvit, Odelia Amit, Uri Greenbaum, Ronit Gold, Yair Herishanu, Noam Benyamini, Irit Avivi, Ron Ram
Chimeric antigen receptor T-cells (CAR-T) are widely used for the treatment of relapsed/refractory Diffuse large B cell lymphoma (DLBCL). The data for CAR-T cell therapy in patients with extra-nodal(EN) lymphoma is restricted. We included 126 consecu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5855462c6ce33322e2ba406612a76c9f
https://doi.org/10.21203/rs.3.rs-2262627/v1
https://doi.org/10.21203/rs.3.rs-2262627/v1
Autor:
Ofrat Beyar Katz, Chava Perry, Efrat Luttwak, Inbal Sdayoor, Yael Bar-On, Odelia Amit, Ronit Gold, Yair Herishanu, Noam Benyamini, Sigal Grisariu Greenzaid, Batia Avni, Polina Stepensky, Diana Libster, Dana Yehudai-Ofir, Shimrit Harlev, Liat Sharvit, Tsila Zuckerman, Uri Greenbaum, Irit Avivi, Ron Ram
Publikováno v:
Blood. 140:3816-3817
Autor:
Sarah Israel, Revital Saban, Dina Ben Yehuda, Shlomzion Aumann, Ora Paltiel, Sigal Grisariu, Vladimir Vainstein, Boaz Nachmias, Neta Goldschmidt, Batia Avni, Diana Libster, Eran Zimran, Moshe E. Gatt, Adir Shaulov, David Lavie, Uria Tsubary
Publikováno v:
Blood
Previous studies and meta-analyses addressing COVID-19 in patients with hematological malignancies (HM) have reported dramatically high mortality rates of up to 34% [Vigenthira 2020, Garcia-Suarez 2020, Sharafeldin 2021]. These studies, however, were
Autor:
David Lavie, Diana Libster, Alex Gural, Moshe E. Gatt, Noam Benyamini, Yossef Barshay, Chezi Ganzel, Adir Shaulov, Batia Avni, Neta Goldschmidt
Publikováno v:
American Journal of Hematology. 92:131-135
Multiple myeloma (MM) and primary systemic light chain amyloidosis (AL) are both chronic plasma cell dyscrasias with different clinical expression but limited treatment options for relapsed refractory disease. We report the effect of the addition of
Autor:
Marina Orevi, Alex Gural, David Lavie, Geffen Kleinstern, Neta Goldschmidt, Moshe E. Gatt, Diana Libster, Ora Paltiel, Dina Ben-Yehuda
Publikováno v:
Cancer Chemotherapy and Pharmacology. 77:1053-1060
Outcomes in primary mediastinal B cell lymphoma (PMBL) improved with the introduction of dose intense treatments, consolidation radiotherapy and rituximab. DA-EPOCH-R, which omits radiotherapy has been adopted with worldwide enthusiasm, despite lack
Autor:
Vladimir Vainstein, Diana Libster, Geremy Godefroy, Eyal Rozenbach, Rachel Bar-Shalom, Boaz Nachmias, Neta Goldschmidt, Chezi Ganzel
Publikováno v:
Blood. 134:5358-5358
PET-CT has been widely incorporated in the treatment of diffuse large B cell lymphoma (DLBCL) and Hodgkin's lymphoma (HD) both for staging at diagnosis and for evaluation of response to therapy. Residual FDG-avid lesions at the end of treatment (EOT)
Autor:
Dina Ben Yehuda, David Lavie, Moshe E. Gatt, Vladimir Vainstein, Neta Goldschmidt, Batia Avni, Diana Libster, Sigal Grisariu, Alexander Gural, Marjorie Pick
Publikováno v:
European journal of haematology. 100(5)
Objective Daratumumab is a promising new antimyeloma agent. We report a single center "real-world" series of multiple myeloma (MM) and amyloidosis (AL) patients treated with daratumumab. Methods Forty-one patients were included: 7 second-line MM, 30
Autor:
Adir, Shaulov, Chezi, Ganzel, Noam, Benyamini, Yossef, Barshay, Neta, Goldschmidt, David, Lavie, Diana, Libster, Alex, Gural, Batia, Avni, Moshe E, Gatt
Publikováno v:
American journal of hematology. 92(2)
Multiple myeloma (MM) and primary systemic light chain amyloidosis (AL) are both chronic plasma cell dyscrasias with different clinical expression but limited treatment options for relapsed refractory disease. We report the effect of the addition of